ArticleAntimicrobial agents and chemotherapy2013
Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 137 citations in OpenAlex.
- Beyond lethal doses: sub-MIC levels of multi-class antibiotics induce species- and isolate-dependent biofilm inhibition in gram-negative pathogens.BMC microbiology · 2026Article
- Broad-Spectrum Antimicrobial Activity of a Ruthenium(II) Polypyridyl Complex against Multidrug-Resistant Uropathogens and Biofilms.ACS omega · 2026Article
- Evolutionary adaptations ofMicrobiology spectrum · 2026Article
- Characterization of adaptive evolution strains for the development of triclosan resistance inApplied and environmental microbiology · 2026Article
- Metallo-β-lactamase-producingFrontiers in microbiology · 2026Review
- Ciprofloxacin pre-exposure influences individual cell MIC and heteroresistance of bacteria inside microfluidic droplets.Scientific reports · 2025Article
- Resistance Mechanisms of Fluoroquinolone inAntibiotics (Basel, Switzerland) · 2025Article
- Cystic fibrosis and the clinical biofilm revolution A survey of the Danish CF Center's contribution.Biofilm · 2025Article
- Targeting efflux pumps prevents the multi-step evolution of high-level resistance to fluoroquinolone inMicrobiology spectrum · 2025Article
- Blue benzoquinone from scorpion venom shows bactericidal activity against drug-resistant strains of the priority pathogen Acinetobacter baumannii.The Journal of antibiotics · 2025Article
- Antibiotic Concentrations in Aquatic Environments of the African Continent: A Systematic Review and Predicted No-Effect Concentration (PNEC) Assessment.Environmental health insights · 2025Review
- The impact of antioxidant-ciprofloxacin combinations on the evolution of antibiotic resistance in Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2024Article
- The SOS Response Activation and the Risk of Antibiotic Resistance Enhancement inInternational journal of molecular sciences · 2024Article
- Article
- Increased susceptibility to azithromycin of Pseudomonas aeruginosa biofilms using RPMI 1640 testing media.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2024Article
- Review
- Spontaneous mutations and mutational responses to penicillin treatment in the bacterial pathogenMarine life science & technology · 2024Article
- The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity ofmBio · 2024Article
- Rolling the evolutionary dice:Microbiology spectrum · 2024Article
- Comparative molecular profiling of multidrug-resistantJAC-antimicrobial resistance · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dynamics of occurrence and the genetic basis of ciprofloxacin resistance were studied in a long-term evolution experiment (940 generations) in wild-type, reference strain (PAO1) and hypermutable (PAOΔmutS and PAOMY-Mgm) P. aeruginosa populations continuously exposed to sub-MICs (1/4) of ciprofloxacin. A rapid occurrence of ciprofloxacin-resistant mutants (MIC of ≥12 μg/ml, representing 100 times the MIC of the original population) were observed in all ciprofloxacin-exposed lineages of PAOΔmutS and PAOMY-Mgm populations after 100 and 170 generations, respectively, and in one of the PAO1 lineages after 240 generations. The genetic basis of resistance was mutations in gyrA (C248T and G259T) and gyrB (C1397A). Cross-resistance to beta-lactam antibiotics was observed in the bacterial populations that evolved during exposure to sublethal concentrations of ciprofloxacin. Our study shows that mutants with high-level ciprofloxacin resistance are selected in P. aeruginosa bacterial populations exposed to sub-MICs of ciprofloxacin. This can have implications for the long-term persistence of resistant bacteria and spread of antibiotic resistance by exposure of commensal bacterial flora to low antibiotic concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.